Who owns ARS Pharmaceuticals, Inc. (ALTUQ)? Elite investor 13F holders

3 tracked elite investors reported holding ARS Pharmaceuticals, Inc as of 2026-09-30, including Rubric Capital, Third Point, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Rubric CapitalArs Pharmaceuticals IncSHARE2026-09-302026-11-16 00:00:0036811111.00 USD8540861.000000SharesholdOriginal filing
Third PointArs Pharmaceuticals IncSHARE2026-09-302026-11-16 00:00:004310000.00 USD1000000.000000SharesholdOriginal filing
Renaissance Technologies LLCArs Pharmaceuticals IncSHARE2026-09-302026-11-12 00:00:00750802.00 USD174200.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown